iifl-logo

Syngene International Ltd Board Meeting

630.1
(-3.57%)
Apr 25, 2025|12:00:00 AM

Syngene Intl. CORPORATE ACTIONS

26/04/2024calendar-icon
26/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting23 Apr 20258 Apr 2025
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve the audited standalone and consolidated financial results for the quarter and year ending March 31 2025; and to consider the recommendation of final dividend if any. Outcome of the Board Meeting - April 23, 2025. (As Per BSE Announcement Dated on:23.04.2025)
Board Meeting23 Jan 202513 Jan 2025
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ending December 31 2024 amongst other routine matters. Outcome of the Board Meeting - January 23, 2025 (As Per BSE Announcement Dated on: 23/01/2025)
Board Meeting23 Oct 20244 Oct 2024
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ending September 30 2024 amongst other routine matters. Outcome of the Board Meeting - October 23, 2024. (As Per BSE Announcement dated on 23.10.2024)
Board Meeting24 Jul 202428 Jun 2024
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ending June 30 2024 amongst other routine matters Outcome of the Board Meeting - July 24, 2024. (As per BSE Announcement Dated on 24/07/2024)

Syngene Intl.: Related News

Syngene Reports ₹1,018 Crore Revenue in Q4 FY25
24 Apr 2025|01:21 PM

The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.

Read More
Syngene International reports better than expected Q4 results
24 Apr 2025|11:36 AM

The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.

Read More
Syngene Boosts Biologics Capacity with US Facility Acquisition
13 Mar 2025|01:40 PM

This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.

Read More
Syngene Reports 18% Profit Surge in Q3, Revenue Up 10.6%
24 Jan 2025|12:45 PM

The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.